OTC Markets EXMKT - Delayed Quote USD

RVL Pharmaceuticals plc (RVLPQ)

Compare
0.0001 0.0000 (0.00%)
As of October 24 at 4:00 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Brian A. Markison Chairman, President, CEO & Principal Financial Officer 525k -- 1959
Mr. James D. Schaub Executive VP & COO 367.2k -- 1982
Mr. Christopher A. Klein General Counsel 367.2k -- 1964
Mr. Michael J. DePetris Principal Accounting Officer -- -- 1977
Mr. Jarret Miller Executive Vice President of Human Resources -- -- --
Scott Schroppe Secretary -- -- --

RVL Pharmaceuticals plc

400 Crossing Boulevard
Bridgewater, NJ 08807
United States
908 809 1300 https://www.rvlpharma.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
125

Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Corporate Governance

RVL Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 28, 2024 at 12:30 PM UTC - November 2, 2024 at 12:30 PM UTC

RVL Pharmaceuticals plc Earnings Date

Recent Events

February 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 20, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 28, 2023 at 12:00 AM UTC

SC 13D/A: Tender Offer/Acquisition Reports

November 27, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 20, 2023 at 12:00 AM UTC

25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured

November 16, 2023 at 12:00 AM UTC

DEF 14A: Proxy Statements

November 6, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 1, 2023 at 12:00 AM UTC

SC 13D/A: Tender Offer/Acquisition Reports

October 20, 2023 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers